Emyria Limited (Emyria or the Company), a data-driven drug development company, is pleased to announce the appointment of global pharmaceutical expert, Dr. Karen Smith to Chair Emyria’s Strategic Advisory Board.
Emyria’s Managing Director, Dr. Michael Winlo, said: “We’re delighted to welcome Dr. Karen Smith to Chair our Strategic Advisory Board. Dr. Smith is a highly acclaimed and respected pharmaceutical executive, who has overseen multiple successful drug registrations. Dr. Smith has held key Chief Executive Officer and Chief Medical Officer roles at some of the most innovative Biotech and Pharmaceutical development companies in the world including holding the role of CMO and Head of R&D at Jazz Pharmaceuticals, which recently acquired GW Pharma for $7.2B. GW’s FDA approved product is a formulation of CBD for a type of epilepsy. We believe Dr. Smiths’ background in successful product registration and strategic partnerships in biopharma will benefit Emyria’s globally-focussed drug registration initiatives, including our EMD-003 product candidate for psychological distress and the symptoms of anxiety, depression and stress.”
Dr. Karen Smith, said: “I’m passionate about supporting innovative ways to accelerate drug development. Emyria has built a unique clinical service and evidence-generating model that has the potential to accelerate drug development for patients with unmet needs. I look forward to assisting the team make progress on its global drug registration goals.”
.jpg){kind=tracking}
